Psychedelic Inspired Medicines

April 2021

NEO
MMED

NASDAQ
MNMD

DE
MMQ

MindMed
Discover. Develop. Deploy.

www.mindmed.co
Disclaimer

Market and Industry Data

This presentation by Mind Medicine (MindMed) Inc. (the “Presentation”) includes market and industry data that has been obtained from third-party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third-party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

CAUTIONARY NOTE ON FORWARD LOOKING INFORMATION

This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking information”) with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approval, the likelihood of obtaining patients or the efficacy of such patients once granted, and the potential for the markets that MindMed is anticipating to access. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed’s ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there could be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed not electing to proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful.

To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed’s financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may not be appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted.

Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein.
Leadership Team - Diverse & Extensive Biotech Experience

JR Rahn
Co-Founder, Director & CEO

JiR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines.

He spent 2 years researching and began personally investing in psychedelic research through his investment company. JiR partnered with drug development veterans Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JiR worked in market expansion and operations at Uber.

Dr. Miri Halperin Wernli, PhD
Executive President, Board Director, Head of Development

Dr. Halperin Wernli co-founded Cresco Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2019. Prior to founding Cresco Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, ROCHE and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.

Robert Barrow
Chief Development Officer

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usvca Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usvca’s development programs. Prior to joining Usvca, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of nephrology, rheumatology, immunology and cardiovascular disease. Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Dan Karlin, MD MA
Chief Medical Officer

Dan previously co-founded HealthMode in 2018 and served as CEO. Before that, he built and led, clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Before that, he was the founder and Chief Medical Officer at Column Health in 2013, a leading technology-enabled psychiatry and addiction practice. He is a strategic Advisor, Otsuka Pharmaceuticals, Click Therapeutics, Synopsia, Recovery Delivered, RightWear. He is also a founding Advisor of the Digital Biomarkers Journal, founder and Board Member, Digital Medicine Society (DMS), and is on committee Leadership Digital Drug Development Tools at Critical Path Alzheimer’s Disease, MJIF, and Mental Health IT. APA, Dan is board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is also an assistant Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA) and Clinical Informatics (MA), Columbia University, Medicine (MD), University of Colorado School of Medicine.

Carol Nast
Chief Operating Officer

Carol has spent her career in executive level positions with large multinational companies and early stage companies in the medical industry. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has lead successfully the development and commercialization of over 100 products. Carol was CDO at NuGen, a genomics company, and served in executive level positions at Indaba Therapeutics (Nadlar), Syva (a division of Syntax Pharmaceuticals). BioRoad and Pfizer. Her passion is the successful launch and adoption of breakthrough products in emerging markets that have significant impact by solving vexing challenges.

Bradford Cross
Chief Technology Officer

MindMed Has Pioneered a New Asset Class

Psychedelic Inspired Medicine is The Latest Advancement in Biotech

**Corporate Strategy & Thesis:**
- Patients deserve more effective medicine and therapies for mental health and addiction
- Most diversified & extensive psychedelic development pipeline in the psychedelics industry
- Aquisitive clinical trial approach is cost efficiency and effective
- Unique focus on all stages of development and delivery - From discovery to insurance

**Institutional Market Momentum:**
- Government: DARPA ($27 million USD)
- Big Pharma: Johnson & Johnson Phase 1 to Approval (Spravato)
- Universities: Johns Hopkins University, University Hospital Basel, NYU Langone School of Medicine, Maastricht University

**Strict Regulatory Adherence & FDA Process:**
- Open IND - (Investigational New Drug)
- Approval by the Institutional Review Board
- Conduct research under Schedule 1 License from DEA (if compound is schedule 1)
- Complete usual clinical trial process for approval

**Breakthrough Therapy Designation (BTD):**
- Others have already received three designations in psychedelics

---

$4.7B
Global annual Anxiety drug sales

$9.5B
Global annual ADHD drug sales

$5.8B
Global annual Anti-Addiction drug sales

$9.6B
Global annual Depression drug sales

$4.7B
Global annual Anxiety drug sales

$9.5B
Global annual ADHD drug sales

$5.8B
Global annual Anti-Addiction drug sales

$9.6B
Global annual Depression drug sales

$4.7B
Global annual Anxiety drug sales

$9.5B
Global annual ADHD drug sales

$5.8B
Global annual Anti-Addiction drug sales

$9.6B
Global annual Depression drug sales
# Mental Health: The $16 Trillion Elephant in the Room

Global Mental Health Cost Expected to total $16 trillion through 2030

<table>
<thead>
<tr>
<th>Mental Health Issue</th>
<th>Statistics</th>
<th>Cost Calculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>284 M</td>
<td>$1 Trillion per year in lost global productivity due to anxiety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Globally suffer from anxiety</td>
</tr>
<tr>
<td>Addiction</td>
<td>300 M</td>
<td>$2.5 Trillion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amount of Annual Opioid Prescriptions in the US</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cost of the Opioid Epidemic to the United States economy over four years</td>
</tr>
<tr>
<td>ADHD</td>
<td>16 M</td>
<td>$194 Billion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Adult ADHD Sufferers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lost productivity Annually in the US</td>
</tr>
</tbody>
</table>

---

### Global Mental Health Cost

- **Anxiety:**
  - Globally suffer from anxiety: 284 M
  - $1 Trillion per year in lost global productivity due to anxiety

- **Addiction:**
  - Amount of Annual Opioid Prescriptions in the US: 300 M
  - $2.5 Trillion

- **ADHD:**
  - US Adult ADHD Sufferers: 16 M
  - $194 Billion

---

**Source:** [US Centers for Medicare & Medicaid Services](https://www.cms.gov)

---

### CMS Spend on OUD & Withdrawal Drugs ($Millions USD)

- **2015:** $2,051
- **2016:** $2,270
- **2017:** $2,554
- **2018:** $2,651
- **2019:** $3,095
- **2020:** $3,042

---

**Drugs:**
- Buprenorphine + Naloxone
- Naltrexone
- Methadone
- Naloxone
- Buprenorphine
- Lofexidine

---
Current Solutions Are Not Working

Anxiety:

+67%  
Increase in benzodiazepine prescriptions (1996-2013) 11

36%  
of patients actually seek treatment 14

Addiction:

+395%  
Increase in Overdose Deaths Involving Prescription Opioids 1999-2018 7

88%  
of patients relapse when buprenorphine/naloxone therapy is tapered 7

ADHD:

+123%  
Increase in ADHD prevalence 1

89.1%  
Individuals not receiving treatment 11

LSD May be a Safer Alternative

Benzodiazepines are 2x more harmful than LSD 10

Emergency Room visits involving illicit drugs, 2011 15

<table>
<thead>
<tr>
<th>Substance</th>
<th>ER Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>505,224</td>
</tr>
<tr>
<td>Heroin</td>
<td>258,482</td>
</tr>
<tr>
<td>Cannabinoids</td>
<td>479,560</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>159,840</td>
</tr>
<tr>
<td>LSD</td>
<td>4,819</td>
</tr>
<tr>
<td>% of Total ER Visits</td>
<td>0.34% of ER visits</td>
</tr>
</tbody>
</table>
# A New Treatment Paradigm

**Product Delivery Categories**

## Non-Hallucinogenic

- LSD Microdosing for ADHD
- 18-MC for Addiction

**How It's Done**
- Derived from psychedelics, negligible hallucination effect

**How It's Delivered**
- Doctor prescription
- Pharmacy pickup and take-home

## Hallucinogenic

- LSD Experiential Therapy for Anxiety
- LSD Experiential for Cluster Headaches

**How It's Done**
- A high dose or “experiential” dose of psychedelics

**How It's Delivered**
- Overseen by therapist & doctor
- In-clinic treatment only
MindMed Is Collaborating With Leading Psychedelic Researchers

Clinical Researchers With Psychedelic Research Experience Are Rate Limiting Factors

University Hospital Basel’s Liechti Lab
- Acquired 10+ years of valuable research & data
- Most valuable LSD data for drug development
- 17 completed or ongoing clinical trials of psychedelics

Maastricht University
- Leading research experts for microdosing of psychedelics
- Phase 2a Clinical Trial - Adult ADHD

Professor Dr. Matthias Liechti, PhD & M.D.
Leader of Liechti Lab at University Hospital Basel

Dr. Kim Kuypers PhD

Dr. Peter Gasser M.D.
"Meet the Only Doctor in the World Legally Allowed to Use LSD to Treat Patients" - VICE

Matthew W. Johnson, PhD
Leading expert at Johns Hopkins University Center for Psychedelic Research
A Process To Build The New Treatment Paradigm

**Discover**
- Acquire new chemical entities and other psychedelics through strategic partnerships and collaborations

**Develop**
- Take compounds through FDA regulated clinical trials while partnering with pharmaceutical companies

**Deploy**
- Build strategic alliances with hospitals, research centers, and ultimately insurers that will license our protocols and drugs

**MINDMED DISCOVER + MINDSHIFT**
University Hospital Basel

- **17** Trials Completed or Ongoing

**DEVELOP - MINDMED PROGRAMS**

- **3** Commercial Trials

**DEPLOY - NYU & ALBERT**
Digital Medicine Platform
NYU Training Program
### Broadest & Most Diversified Pipeline of Psychedelic Drugs in Clinical Development and R&D

Pipeline Diversification Offers Access To Full Spectrum Of Psychedelic Inspired Medicines

<table>
<thead>
<tr>
<th>CLINICAL TRIALS</th>
<th>PRE-DISCOVERY</th>
<th>DISCOVERY</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1A</th>
<th>PHASE 1B</th>
<th>PHASE 2A</th>
<th>PHASE 2B</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSD Experiential Therapy</td>
<td>Anxiety - Project Lucy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-MC</td>
<td>Opioid Withdrawal/SUD - Project Layla</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSD Microdosing</td>
<td>Adult ADHD - Project Flow</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MINDMED DISCOVER** University Hospital Basel

- LSD Assisted Therapy
- Cluster Headaches
- Multiple ongoing or completed: on LSD, MDMA, DMT, Psilocybin

![Pipeline Diagram](image-url)
Develop: Commercial Drug Trials
Value through clinical trial acquisitions:

Acquired ongoing Phase 2 Anxiety clinical trial from UHB led by Dr. Peter Gasser & Dr. Matthias Liechti

LSD Development Plan:

Based on industry averages, this saves roughly $8.4 to $26.2 million in non-dilutive financing costs and 4+ years of time

Currently preparing to open the IND with a Phase 2 Study

Plan to file IND Q3 2021
**Develop: LSD Microdosing Phase 2a Clinical Trial**

Proof of Concept Using Sub-perceptual Amounts of LSD (Microdose)

**Dr. Kim Kuypers** will serve as Principal Investigator for Maastricht site

**Dr. Matthias Liechti** will serve as Principal Investigator for the Basel site

---

**Clinical Trial Progress and Details:**
- Phase 2a anticipated to begin in Q3 2021 in Europe
- Low dose LSD (20 mcg) compared with a placebo administered for 6 weeks

**Locations:**
- Maastricht (Netherlands)

---

Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:
- Increase focus
- Decrease anxiety
- Increase creativity
- Improve mood

*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed’s control*
18-MC: Creating the Antibiotic of Addiction

Addressing Addiction as a Brain Disease

How 18-MC regulates dopamine

Dopamine dysregulation is not corrected in patients

How current medications work:

Repeated Opioid Use
Addiction
Current Treatment

Dopamine level (Low to high)
Dopamine baseline
Develop: 18-MC Development Plan

Finishing Phase 1 MAD/ SAD & Preparing Phase 2a Opioid Withdrawal Q3 2021

18-MC Development Timeline

- **Phase 1 SAD/MAD Trial**
  - Q3 2020

- **Start of Phase 2a**
  - Q1 2021

- **End of Phase 2a/Start of Phase 2b**
  - Q3 2022

- **Start of Phase 3**
  - Q1 2023

- **NDA Submission to FDA**
  - Q4 2025

Phase 2a Trial Design:

- **Single Ascending Dose:** Ongoing
- **Multiple Ascending Dose:** Ongoing
- **Investigating the efficacy of 18-MC in mitigating the symptoms of opioid withdrawal**
- **Three cohorts:** High Dose, Low Dose, Placebo
- **Participants will be treated for 8-days while undergoing opioid detox**
- **32 patients per cohort**
- **Management of withdrawal symptoms compared with placebo**
- **Proportion who complete the trial compared with placebo**

*Management estimates; actual timeline will depend on results, approvals and other factors outside of MindMed’s control*
Discover

Early Stage R&D and Psychedelic Drug Discovery
MindMed is working with the Liechti Lab to research and develop next-gen therapies, compounds, and dosing technologies.

We have an exclusive license for DMT, MDMA, LSD and Psilocybin.

13 Trials Completed
4 Ongoing
Each stage of the process will generate an evolving family of intellectual property including:

- Composition of matter and methods of manufacturing
- Claims covering a library of homologues
- New indications
- Formulations

- Digital Methods & Products
- AI and ML algorithms and models
- Drug + drug combination therapies
- Drug + device combination therapies
- Dosing protocols

Patents on known substances such as LSD can be obtained based on:

- A new use or disease indication
- Unique treatment modality (dose or regimen)
- Finding unique chemical properties (polymorph, salt form, etc.) that:
  - May work better than the known substance;
  - May have better biopharmaceutical properties; or
  - Include novel combinations of known substances
IP Example: Putting the Patient & Therapist in Control
Potential to Improve the Safety & Patient Experience

LSD Neutralizer:
A substance with the expected ability to abort the hallucinogenic effects of LSD within 20 to 30 minutes

Purpose & Use Cases
- Shorten and stop LSD trips while giving the patient and therapist control
- End experiential therapy in progress
- Abuse deterrence
- Researching how the substance might be time-released within another compound

Intellectual Property Status:
- MindMed and University Hospital Basel have filed a patent application in the US, which preserves worldwide rights

Provide therapists and medical professionals with the tools to control LSD effects in a clinical setting
Discover: MindMed & MindShift Create the Discovery Division
Developing Novel Compounds Derived from Psychedelic Substances or Synthesized from Existing Compounds

Engineering a portfolio of compounds & formulations that are expected to demonstrate variations in:

- Onset of action
- Duration
- Potency
- Safety
- Receptor Selectivity

The Novel Compounds (or Chemical Structures) will be:

- Derivatives of existing compounds
- Potentially enhanced versions of established and classic psychedelic compounds
- Compounds with expected combined psychedelic-empathogenic effect profiles

MindShift is expected to enable MindMed to bring a new line of psychedelic compounds into trials
Discover: Groundbreaking LSD Microdosing Study Using Digital Clinical Markers

Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

Combining LSD & Digital to Understand Effects On:

- BDNF plasma levels
- Sleep measures
- Quality of life
- Mood
- Cognitive performance
- Immune system response

World-Leading Researchers

- Led by *Dr. Kim Kuypers*
Deploy
Psychedelic Drug Delivery
Long-term Commitment to Solving Mental Health Issues:

- MindMed is committing $5 million over a five-year period
- Initial focus on substance use disorders including opioid addiction and alcoholism
- Catalyze efforts to recruit and train more psychiatrists and clinical investigators

Managed by NYU’s Seasoned Clinical Experts

Michael Bogenschutz, M.D.
Primary investigator leading the effort towards FDA approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder

Stephen Ross, M.D.
World leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist
Introducing Albert: The Digital Medicine Division for Psychedelics

The Future of Modern Medicine Relies on Measurement

More than 60% of all counties in the US - including 80% of all rural counties do not have access to a psychiatrist.

Measure

- Measurements use to improve efficiency & efficacy of clinical development and clinical care

Analyze

- Focused on medical meaning & regulatory acceptance

Commercialize

- Enables remote medicine, personalized patient care, & clinical care optimization

A data driven, technology integrated, patient centered engine for efficient discovery, development, and deployment of psychedelic inspired medicines and digital companion treatments.
Immediate Uses & Commercial Impact of the Albert Division
Technology Integration Can Enhance All Phases of the Clinical Paradigm

Areas of Immediate Impact:
- Clinical Trials
- Disease Diagnosis
- Remote Patient Monitoring
- Treatment Matching & Selection
- Relapse Prevention
- Adherence Monitoring

COVID-19 has precipitated a wider scale need for adoption of:
- Telehealth and remote care modalities
- Remote clinical trials

Telehealth visits up +1000% during COVID-19 pandemic

New partnerships driven by software
Lead to near-term revenue

- Novartis
- NIH
- Sema4
- Merck
- Winsantor
- Biocure
- Helmsley
- Evidation
Near Term Inflection Points For MMED

MindMed Is Capitalizing On Opportunity

Near Term Inflection Points Timeline:

- Open IND for LSD anxiety
- Launch Phase 2a study of 18-MC in Opioid Withdrawal
- Launch Phase 2 study of LSD microdosing in ADHD
- Launch Phase 2b study of LSD in anxiety
- Results of LSD-assist study (UHB collaboration)
- Topline Phase 2 results for 18-MC
- Topline Phase 2 results for LSD
NASDAQ: MNMD // NEO: MMED // DE: MMQ

First Publicly Listed Psychedelic Biotech Company

### Share Ownership (As of 2/16/2021)

<table>
<thead>
<tr>
<th>Share Ownership</th>
<th>Shares</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Team/Directors/Insiders</td>
<td>74,985,214</td>
<td>17.3%</td>
</tr>
<tr>
<td>Non-insider shares</td>
<td>310,098,149</td>
<td>71.4%</td>
</tr>
<tr>
<td>Equity Incentive Plan (Issued)</td>
<td>23,742,427</td>
<td>5.5%</td>
</tr>
<tr>
<td>Outstanding Warrants</td>
<td>25,599,807</td>
<td>5.9%</td>
</tr>
<tr>
<td>Total (Fully diluted)</td>
<td>434,425,597</td>
<td>100%</td>
</tr>
<tr>
<td>Number of Shareholders</td>
<td>200,000+</td>
<td></td>
</tr>
</tbody>
</table>

### $204M USD Raised since inception (including warrants)

**Markets Cap USD:** $1.6 billion April 27th ($4.69 price per share)

**Markets Cap CAD:** $1.9 billion April 27th ($5.84 price per share)

**Strong investor backing**

- Seed Round Aug '19: $6m USD
- Pre-Public Feb '20: $24m USD
- Bought Deal Financing May '20: $10m USD
- Bought Deal Financing Oct '20: $22m USD
- Bought Deal Financing Dec '20: $27m USD
- Bought Deal Financing Jan '21: $72m USD
- Bought Deal Financing March '21: $15.4m USD
JR Rahn is a former Silicon Valley tech executive. JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded.

Dr. Miri Halperin, PhD previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.

Bruce Linton is an activist investor with SLANG Worldwide Inc. (CSE:SLNG). Activist investor with OG DNA Genetics Inc Founder and Former Chairman and CEO of Canopy Growth Corporation (CGC/WEED). Bruce chairs the board’s Compensation, Governance and Nominating Committee.

Stephen Hurst has more than thirty-five years’ experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.

Perry Dellelce is a managing partner of Wildeboer Dellelce LLP. He also serves as chair of the NEO Exchange, Canada’s newest stock exchange. Board Member of Mount Logan Capital Inc. and Lendified Inc.

Brigid Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhaled Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board’s Audit Committee.
A Track Record of Success Across Several Industries

Jeanne Bonelle
EVP, Technical Operations

Jeanne has established quality systems within the developmental phase for a wide range of products, including Senior Director of Quality Assurance at Inhale Therapeutics Systems, Inc. (now Nektar Therapeutics, Inc.); Director of Quality Assurance at CholesTech Inc. (now Alere Inc.); Manager of Quality Assurance at BioResponse Inc. (now Baxter Health Care).

Dave Guebert
Chief Financial Officer

Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then, he has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry.

Carole Abel
Vice President, Programs & Europe

Carole has over 23 years of experience in multidisciplinary environments, including 15 years in the pharma industry in Switzerland (Astellion Pharmaceuticals and Creso Pharma). She has been successfully leading cross-functional teams and directing groups in different areas: operations, project management, and process improvements. Over the last few years, Carole has been instrumental in the preparation and coordination of corporate audits and due diligence activities.

Collin Gage
Vice President of Corporate Development

Collin began his career at Point72 Asset Management. From there, he worked at the Gen讥ks Family Office. While at Gen讥ks he was responsible for selecting and researching alternative investments, expansionary efforts, and capital management. Gen讥ks is the family office of a former Fortune 50-C-Level executive. During this period, Collin also helped co-found a biotech focused venture capital fund called Prekift Capital.

Madeline Feldman
Director of Operations & Administration

Madeline has a background supporting startups through corporate innovation and investor relations, fundraising for venture capital funds and non-profit organizations, and building out operational departments in various industries. She has a love for performing arts and works with artists in creating and producing stage shows for major venues and resorts.

Nico Forte
Senior Director, Business Operations and Development

Nico has more than twenty-five years of marketing and business development experience primarily in the biopharma and medical device industries. His background includes RIA agency marketing and communication work for British-American and Mead Johnson. Onology divisions as well as business development roles for Inhale Therapeutics Systems, Inc. (now Nektar Therapeutics, Inc.).

Donald Gehlert, PhD
Chief Scientific Officer

Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology. During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule Therapies. He also participated on Phase I and Phase II clinical development teams that designed and delivered translational proof of concept studies in the areas of ADH2, obesity, AUD, depression, pain and migraine. He is a co-author on 182 publications and a co-inventor on 15 issued and pending patents.

Shaheera St. John
Vice President, Programs

Shaheera has nearly 20 years of project management experience. As an independent consultant, Ms. St. John supported companies of all sizes from start-up to Fortune 500 companies in biotech, pharma, and medical device. She has worked with various sized teams to help advance programs from early research/MDI through all phases of development, including Phase 2 and commercialization. Ms. St. John obtained her degree in Molecular Cellular and Developmental Biology from the University of California, Los Angeles.

Daniel E. Levy, Ph.D.
Vice President, CMC

Dr. Levy is an experienced organic medicinal chemist having contributed to the design of novel therapeutic agents targeting cardiovascular disease, cancer, inflammatory and CNS disorders. In almost 30 years of contributing to the biopharmaceutical industry, Dr. Levy led interdisciplinary teams focused on finance initiatives, GPCR antagonists, matrix metalloproteinase inhibitors and cell adhesion molecules. His work is documented in almost 10 peer-reviewed publications and over 24 issued/published United States patents.

Rachann McKnight
Director, Business Process

Rachann is a visionary leader, executor, and manager with experience directing startup operations in a growth-minded direction. She has a history of helping early-stages companies scale, building out high-performing teams and business processes, and executing large-scale corporate events — including conferences with 100+ attendees. Rachann is passionate about companies whose primary missions are to use their collective power for good and has led numerous successful diversity and inclusion efforts in support of that collective good.
Scientific Advisory Board - Deep & Relevant Expertise

Stanley D. Glick, PhD  
Scientific Advisor 18-MC

John Rotrosen, MD  
Professor of Psychiatry, NYU Langone

Kenneth Alper, MD  
Clinical Associate Professor of Psychiatry and Neurology

Sarah McCallum, PhD  
Associate Professor of Neuroscience and Experimental Therapeutics

Matthew W. Johnson, Ph.D  
Professor at Johns Hopkins

Jed Rose, PhD  
Professor in Psychiatry and Behavioral Sciences at Duke University

John Blacker, PhD  
Professor of Process Chemistry, University of Leeds

Natalie Wheeler, PhD  
Medical Science Liaison with Dova Pharmaceuticals

Eric Edwards, MD, PhD  
Co-founder and Member, Board of Directors at Kaleo, Inc.

MindMed
# Mindmed in the News

<table>
<thead>
<tr>
<th>Source</th>
<th>Article</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>The Wall Street Journal</em></td>
<td>&quot;Psychedelics: Drug Startup Raises $24 Million Ahead of IPO.&quot;</td>
<td>February 27, 2020</td>
</tr>
<tr>
<td><em>Bloomberg</em></td>
<td>&quot;Its market capitalization of over C$1 billion puts the company ahead of at least eight companies in Canada’s benchmark S&amp;P/TSX Composite Index, according to data compiled by Bloomberg.&quot;</td>
<td>December 9, 2020</td>
</tr>
<tr>
<td><em>Business Insider</em></td>
<td>&quot;A startup that wants to use psychedelics to treat addiction just raised $4.2 million from the host of Shark Tank and the architect behind the world’s biggest cannabis grower.&quot;</td>
<td>September 30, 2019</td>
</tr>
<tr>
<td><em>Fast Company</em></td>
<td>&quot;This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?&quot; – Kevin O’Leary</td>
<td>December 9, 2019</td>
</tr>
<tr>
<td><em>The New Yorker</em></td>
<td>&quot;New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at NYU Langone Medical Center.&quot;</td>
<td>October 12, 2020</td>
</tr>
<tr>
<td><em>Fortune</em></td>
<td>&quot;Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution.&quot;</td>
<td>February 17, 2020</td>
</tr>
<tr>
<td><em>Town &amp; Country</em></td>
<td>&quot;The evidence for psychedelics as medicine is far greater than that for CBD, which companies are selling to relieve ills from Parkinson’s to Crohn's.&quot;</td>
<td>April 13, 2020</td>
</tr>
</tbody>
</table>

*MindMed named one of 36 startups that could change the world* December 17, 2019


